N'-hydroxy-2-(3-(trifluoromethyl)phenyl)acetimidamide | 128104-39-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N'-hydroxy-2-(3-(trifluoromethyl)phenyl)acetimidamide
• 英文别名: N′-hydroxy-2-(3-(trifluoromethyl)phenyl)-acetimidamide；N-Hydroxy-2-(3-trifluoromethyl-phenyl)-acetamidine；N'-Hydroxy-2-(3-trifluoromethylphenyl)ethanimidamide；N'-hydroxy-2-[3-(trifluoromethyl)phenyl]ethanimidamide
• CAS: 128104-39-2
• 化学式: C₉H₉F₃N₂O
• 分子量: 218.178
• InChiKey: QEYLQLHFBVNBCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N'-hydroxy-2-(3-(trifluoromethyl)phenyl)acetimidamide 在 吡啶 、 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 以24%的产率得到4-[[(3-trifluoromethyl)phenyl]methyl]-3H-1,2,3,5-oxathiadiazole 2-oxide
  参考文献：
  名称：

  Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as

  摘要：

  该发明涉及新型苄基-3H-1,2,3,5-噻二唑二氧化物，以及其制备方法、化合物的使用方法和药物制剂。这些化合物具有药理特性，可用于治疗糖尿病及相关病症。

  公开号：

  US04895862A1
• 作为产物：
  描述：

  间三氟甲基苯乙腈 在 盐酸羟胺 、 sodium methylate 作用下， 以 甲醇 为溶剂， 以21%的产率得到N'-hydroxy-2-(3-(trifluoromethyl)phenyl)acetimidamide
  参考文献：
  名称：

  Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as

  摘要：

  该发明涉及新型苄基-3H-1,2,3,5-噻二唑二氧化物，以及其制备方法、化合物的使用方法和药物制剂。这些化合物具有药理特性，可用于治疗糖尿病及相关病症。

  公开号：

  US04895862A1

文献信息

• Piperidinylpyrazolopyrimidinones and their use
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10118930B2

  公开（公告）日：2018-11-06

  The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代的哌啶基吡唑嘧啶酮、其制备工艺、化合物在治疗和/或预防疾病的方法中的单独使用或组合使用，特别是用于治疗和/或预防有或没有潜在遗传性或获得性止血障碍的患者的急性和复发性出血、其中，出血与疾病或医疗干预有关，这些疾病或医疗干预选自月经大量出血、产后出血、失血性休克、出血性膀胱炎、胃肠道出血、创伤、手术、移植、中风、肝脏疾病、遗传性血管性水肿、鼻出血以及血汗管病后的滑膜炎和软骨损伤组成的组。
• Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma
  作者：Song Liu、Jing Sui、Baozhu Luo、Jiangnan Zhang、Xinrong Xiang、Tao Yang、Youfu Luo、Jie Liu

  DOI：10.1021/acs.jmedchem.4c00080

  日期：2024.7.11

  ADX-47273). Mechanistically, SL44 induces degradation of respiratory chain complex subunits and leads to apoptosis in HCC cells. In vivo results demonstrated that SL44 has potent tumor growth inhibitory activity and has a superior safety profile compared to the kinase inhibitor sorafenib. Overall, we developed a novel class of HsClpP agonists that can potentially be used for the treatment of HCC.

  人酪蛋白分解酶 P (HsClpP) 的化学激动作用因其在维持线粒体稳态中的关键作用而日益被认为是一种潜在的抗癌策略。我们发现了 5-(哌啶-4-基)-1,2,4-恶二唑衍生物作为一类新型 HsClpP 激动剂，并首次证明了 HsClpP 激动剂在肝细胞癌 (HCC) 治疗中的应用（佩斯，A.；皮耶罗，P. 1,2,4-恶二唑的新时代。组织。生物分子。化学。 2009 , 7 (21), 4337-4348)。化合物SL44在α-酪蛋白水解测定中表现出有效的HsClpP激动活性（EC 50 = 1.30 μM）并抑制HCCLM3细胞的增殖（IC 50 = 3.1 μM，比命中的ADX-47273高21.4倍）。从机制上讲， SL44诱导呼吸链复合体亚基降解并导致 HCC 细胞凋亡。体内结果表明， SL44具有有效的肿瘤生长抑制活性，并且与激酶抑制剂索拉非尼相比具有优越的安全性。总体而言，我们开发了一类新型
• Discovery of Potent and Selective SH2 Inhibitors of the Tyrosine Kinase ZAP-70
  作者：Chi B. Vu、Evelyn G. Corpuz、Taylor J. Merry、Selvaluxmi G. Pradeepan、Catherine Bartlett、Regine S. Bohacek、Martyn C. Botfield、Charles J. Eyermann、Berkley A. Lynch、Ian A. MacNeil、Mary K. Ram、Marie Rose van Schravendijk、Shelia Violette、Tomi K. Sawyer

  DOI：10.1021/jm990229t

  日期：1999.10.1

  A series of 1,2,4-oxadiazole analogues has been shown to be potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70, a potential therapeutic target for immune suppression. These compounds typically are 200-400-fold more potent than the native, monophosphorylated tetrapeptide sequences. When compared with the high-affinity xi-1-ITAM peptide (Ac-NQL-pYNELNLGRREE-pYDVLD-NH2, wherein pY refers to phosphotyrosine) some of the best 1,2,4-oxadiazole analogues are approximately 1 order of magnitude less active. This series of compounds displays an unprecedented level of selectivity over the closely related tyrosine kinase Syk, as well as other SH2-containing proteins such as Src and Grb2. Gel shift studies using a protein construct consisting only of C-terminal ZAP-70 SH2 demonstrate that these compounds can effectively engage this particular SH2 domain.
• Antihyperglycemic activity of novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides
  作者：John W. Ellingboe、Thomas R. Alessi、Terence M. Dolak、Thomas T. Nguyen、John D. Tomer、Frieda Guzzo、Jehan F. Bagli、Michael L. McCaleb

  DOI：10.1021/jm00085a002

  日期：1992.4

  A series of substituted 3H-1,2,3,5-oxathiadiazole-2-oxides (6) was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. The oxathiadiazoles 6 were synthesized by a two-step sequence: treatment of a substituted acetonitrile (4) with hydroxylamine to give the corresponding amidoxime (5) and cyclization with thionyl chloride to yield 6. In terms of potency, the 2-naphthalenylmethyl group (as in compound 3) was found to be the optimal substituent in this series. Compound 3 was approximately 5 times more potent than ciglitazone (1).
• ALESSI, THOMAS R.;DOLAK, TERENCE M.
  作者：ALESSI, THOMAS R.、DOLAK, TERENCE M.

  DOI：——

  日期：——